Related Experiment Video
Updated: Jun 15, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Nifedipine preparations on the Belgian market: a comparative study
K De Braekeleer1, C Fierens, J Corthout
1Service de Contrôle des Médicaments APB, Bruxelles.
Journal De Pharmacie De Belgique
|February 27, 2010
Summary
Nifedipine capsules and tablets met quality standards, but prolonged-release tablets showed significant differences in dissolution, indicating they are not interchangeable. This impacts generic nifedipine substitution for patients.
Area of Science:
- Pharmaceutical Sciences
- Analytical Chemistry
Background:
- Nifedipine is a widely used calcium channel blocker for hypertension and angina.
- Evaluating generic drug products ensures therapeutic equivalence and patient safety.
Purpose of the Study:
- To assess the quality and interchangeability of nifedipine immediate-release capsules and prolonged-release tablets.
- To compare in vitro performance characteristics of different nifedipine formulations.
Main Methods:
- In vitro dissolution testing.
- Assay and content uniformity analysis.
- Determination of related substances (impurities).
- Validation of analytical methods per international guidelines.
Main Results:
- All tested nifedipine preparations met assay and content uniformity requirements.
- Prolonged-release tablets exhibited significant variability in dissolution profiles.
- No major issues were found regarding related compounds in the evaluated nifedipine products.
Conclusions:
- While immediate-release nifedipine capsules and prolonged-release tablets generally meet quality standards, the observed dissolution differences for prolonged-release formulations raise concerns about their interchangeability.
- Physicians and pharmacists should exercise caution when substituting prolonged-release nifedipine products based solely on quality compliance.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...